Diane-Laure Pagès, Co-founder & COO, Orakl Oncology | Slush 2025
summary
Claims an AI+wet‑lab engine that predicts patient drug response with 88% accuracy, trained on a proprietary mix of clinical records and lab‑grown organoids to create hundreds of tumor avatars (pancreatic, colorectal, KRAS‑mutant). Platform is live for clinical‑stage drugs and drug discovery with two products: Operict and Target; it generates causal validation from organoid assays, guides trials, and already powers partnerships with leading pharma and hospitals, aiming to expand to lung cancer and capture multi‑million drug revenue streams.
AI-written summary · about